TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions

Ulcerative Colitis

Interventions

DRUG

Tofacitinib

Tofacitinib alone will be continued at a dose of 11 mg once a day

DRUG

Tofacitinib plus mesalamine

Both tofacitinib 11 mg once a day and mesalamine will be continued

All Listed Sponsors

lead

Post Graduate Institute of Medical Education and Research, Chandigarh

OTHER